COMMUNITY OUTREACH AND ENGAGEMENT ABSTRACT Cancer is the second leading cause of death in Utah, and Huntsman Cancer Institute (HCI) is the official Cancer Center of the State of Utah, pursuant to a 2005 legislative resolution. In recognition of this charge and the fact that >80% of HCI?s cancer patient population is from Utah, HCI defines its catchment area as the State of Utah. Further, HCI also serves as the only National Cancer Institute (NCI)-designated Cancer Center in the vast Mountain West region of the USA that includes Utah, Idaho, Montana, Nevada, and Wyoming. Through thoughtful monitoring of the cancer landscape in Utah, HCI has identified, invested in, and promoted research, prevention, and policy measures to address pressing needs of our catchment area, with the goal to achieve the greatest and most sustainable impact. Three primary focus areas of our efforts include: 1) Melanoma/Sun Safety: Utah has the highest melanoma incidence in the nation; 2) Lung Cancer/Tobacco Control/Radon Reduction: Lung cancer is the leading cause of cancer death in Utah; 3) Rural/Frontier and other Disparity Populations: Major opportunities to address cancer health equity due to Utah's rural/frontier geography and demographics. In addition, we have invested in areas with opportunities for innovation and impact based on features of our catchment area: 1) Top Five Cancers in Utah for Incidence or Mortality; 2) Inherited Cancer Risk; 3) Pediatric/Adolescent Cancers; 4) Prevention of HPV-Related Cancers. HCI?s Community Outreach and Engagement (COE) efforts encompass two major components. The Center for HOPE (Health Outcomes and Population Equity) leads our community-engaged and implementation research efforts to improve cancer-related population health, and the Community Outreach and Prevention Education office provides outreach and education about cancer risk, prevention, and care to patients and communities throughout Utah. HCI has an impressive portfolio of catchment-area relevant research, ranging from basic- science discovery and investigator-initiated clinical trials in our areas of focus, to a recently submitted Melanoma SPORE, and large team science grants that engage Utah?s Federally Qualified Health Centers. Finally, COE efforts align with our educational programs to address health equity, which include our CURE PathMaker Program and GMaP. HCI also works closely with two major community partners, HCI?s 38-member Community Advisory Board and the Utah Cancer Action Network, to establish priorities for services, outreach, education, and research. Through these and other state-wide and broader partnerships, HCI translates science to the community. We have been successful in achieving and continue to drive policy improvements at local and national levels, with particular emphasis on cancer-related topics of relevance to Utah.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA042014-31
Application #
9935890
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
31
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Barrott, Jared J; Illum, Benjamin E; Jin, Huifeng et al. (2018) Paracrine osteoprotegerin and ?-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest 128:207-218
Sample, Danielle C; Samadder, N Jewel; Pappas, Lisa M et al. (2018) Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol 18:115
Delker, Don A; Wood, Austin C; Snow, Angela K et al. (2018) Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prev Res (Phila) 11:4-15
Madsen, Michael J; Knight, Stacey; Sweeney, Carol et al. (2018) Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15. Cancer Epidemiol Biomarkers Prev 27:644-652
Trott, Daniel W; Henson, Grant D; Ho, Mi H T et al. (2018) Age-related arterial immune cell infiltration in mice is attenuated by caloric restriction or voluntary exercise. Exp Gerontol 109:99-107
Wu, Yelena P; Parsons, Bridget G; Mooney, Ryan et al. (2018) Barriers and Facilitators to Melanoma Prevention and Control Behaviors Among At-Risk Children. J Community Health 43:993-1001
Zabriskie, Matthew S; Antelope, Orlando; Verma, Anupam R et al. (2018) A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica 103:e87-e91
Wolff, Roger K; Hoffman, Michael D; Wolff, Erica C et al. (2018) Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. Genes Chromosomes Cancer 57:366-376
Hellwig, Sabine; Nix, David A; Gligorich, Keith M et al. (2018) Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One 13:e0197333
Fleming, Aaron M; Zhu, Judy; Ding, Yun et al. (2018) Human DNA Repair Genes Possess Potential G-Quadruplex Sequences in Their Promoters and 5'-Untranslated Regions. Biochemistry 57:991-1002

Showing the most recent 10 out of 1193 publications